Affinity Asset Advisors LLC Has $6.35 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Affinity Asset Advisors LLC lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,000 shares of the company's stock after selling 5,000 shares during the period. Affinity Asset Advisors LLC owned about 0.15% of Axsome Therapeutics worth $6,346,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in shares of Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after purchasing an additional 27,534 shares during the period. Strategic Financial Concepts LLC purchased a new stake in Axsome Therapeutics in the 4th quarter worth about $2,599,000. Intech Investment Management LLC boosted its holdings in shares of Axsome Therapeutics by 46.5% during the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock worth $1,356,000 after purchasing an additional 5,087 shares during the period. Raymond James Financial Inc. acquired a new position in Axsome Therapeutics in the 4th quarter worth about $14,771,000. Finally, Charles Schwab Investment Management Inc. raised its position in Axsome Therapeutics by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after acquiring an additional 5,438 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Down 0.0 %

NASDAQ AXSM traded down $0.01 during trading on Friday, hitting $104.46. The stock had a trading volume of 486,786 shares, compared to its average volume of 680,288. The company has a market capitalization of $5.09 billion, a PE ratio of -17.44 and a beta of 0.88. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company's 50-day moving average price is $118.16 and its two-hundred day moving average price is $102.46. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AXSM shares. Morgan Stanley upped their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Mizuho raised their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research report on Thursday, March 27th. Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $200.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, April 3rd. Finally, Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $169.80.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.